Announced
Completed
Synopsis
CICC Capital, a Chinese partially state-owned multinational investment management and financial services company, led a $100m Series C round in METiS Pharmaceuticals, a biotechnology company that aims to address unmet clinical needs. The firm will use the proceeds to advance its AI-driven drug delivery and discovery platform.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.